Evidence map›Paper›PMID 34014252›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries.

Caroline E Boeke, Lindsey Hiebert, Imam Waked, Tengiz Tsertsvadze, Lali Sharvadze, Maia Butsashvili, Mamuka Zakalashvili, Win Naing, Neil Gupta, Fredrick Kateera and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Caroline E BoekeClinton Health Access Initiative, Boston, Massachusetts, USA.
Lindsey HiebertCoalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, Georgia, USA.
Imam WakedHepatology Department, National Liver Institute, Menoufia University, Shebeen El Kom, Egypt.
Tengiz TsertsvadzeInfectious Diseases, AIDS, and Clinical Immunology Research Center, Tbilisi, Georgia.
Lali SharvadzeHepatology Clinic Hepa, Tbilisi, Georgia.
Maia ButsashviliClinic Neolab, Tbilisi, Georgia.
Mamuka ZakalashviliClinic Mrcheveii, Tbilisi, Georgia.
Win NaingYangon Speciality Hospital, Yangon, Myanmar.
Neil GuptaPartners in Health/ Inshuti Mu Buzima, Kigali, Rwanda.
Fredrick KateeraPartners in Health/ Inshuti Mu Buzima, Kigali, Rwanda.
Craig McClureClinton Health Access Initiative, Boston, Massachusetts, USA.
John W WardCoalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, Georgia, USA.
Christian B RamersClinton Health Access Initiative, Boston, Massachusetts, USA.
Clinton Health Access Initiative · USThe Task Force for Global Health · USAIDS and Clinical Immunology Research Center · GEEast Yangon General Hospital · MMMenoufia University · EGNeoGenomics (United States) · US

Funding

Coalition for Global Hepatitis EliminationUnited Kingdom Foreign, Commonwealth and Development Office
6 · The paper itself

Abstract

Access to recommended second-line treatments is limited for patients who fail initial hepatitis C virus (HCV) therapy in low- and middle-income countries. Alternative regimens and associated outcomes are not well understood. Through a pooled analysis of national program data in Egypt, Georgia, and Myanmar, we observed SVR rates >90% for alternative retreatment regimens.

Indexed as

Hepatitis CHepatitis C, ChronicAntiviral AgentsDeveloping CountriesDrug Therapy, CombinationGenotypeHepacivirusHumansRetreatmentAntiviral AgentsHCVhepatitis Clow- and middle-income countriesretreatmenttreatment failure

Identifiers

PMID34014252
PMCPMC8835629
OpenAlexW3160956698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.